Analysts point out that growth from product introductions has nearly halved over the last two years as the drug regulator has been more stringent about new combination drugs.
* The growth of the Indian Pharma market has come down from 13.5 percent in FY15 to 10 percent YoY in FY18
* Analysts point out that growth from product introductions has nearly halved over the last two years as the drug regulator has been more stringent about new combination drugs
* Growing awareness about cheaper alternatives to branded generics and more channels providing access to them has started to impact volume growth for branded generics
* The Government’s push towards Jan Aushadhi stores has started to impact volumes of branded generics
* The Pradhan Mantri Jan Aushadhi scheme aims to provide quality drugs at almost 50-90% discount to their branded counterparts
* Jan Aushadhi stores cover a list of 800 plus drugs, both chronic and acute, across therapies like anti-cancer, anti-infective, reproductive, and gastrointestinal medicines
* There are 5000+ Jan Aushadhi stores now and another 2500 to be opened by 2020
* Edelweiss noted that the revenue of the Jan Aushadhi scheme is expected to double YoY in FY19. Payment of Rs 300 crore expected in FY19
* Can potentially disrupt 1% of IPM
# Edelweiss noted that the Rs 120 crore sales of BPPI in FY18 correspond to Rs 600 crore of branded products
# With each store selling Rs 5 lakh worth of medicines, by 2020-21, the scheme topline would be Rs 600 crore
# Assuming an average price differential of 5-times, this can potentially disrupt Rs 25,000-30,000 crore worth of sales of branded generics
# In short, by 2020-21, the Jan Aushadhi scheme has the potential to disrupt 20% of IPM sales
